Novartis AG, of Basel, Switzerland, said it has confirmed five-year data demonstrating sustained efficacy and safety of interleukin-17 inhibitor Cosentyx (secukinumab) in a phase III long-term extension study in patients with moderate to severe plaque psoriasis. Detailed results will be presented at an upcoming medical meeting.